glp-1 elevated liver enzymes Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Current Status of Glucagon-like Peptide-1
Description
GLP-1 receptor agonists are increasingly used to manage type 2 diabetes and support weight management in the UK
As such, postprandial secretion of GIP, GLP-1, and GLP-2 inhibits bone resorption and/or promotes bone formation, representing a gut-bone axis
That cardiovascular indication is a clinically and commercially powerful differentiator
This integrated anti-inflammatory and anti-fibrotic action complements their metabolic benefits, positioning dual GLP-1 receptor agonists as promising agents in the comprehensive management of MASLD and its complications
Otro aspecto decisivo es el soporte al cliente
